Tom Daniel was President, Global Research and Early Development, at Celgene Corporation over the last decade, as the company emerged as a leader in defining new mechanisms for drug action, established industry leading collaborative networks, and advanced and commercialized innovative medicines in oncology and inflammatory diseases. He previously served as Chief Scientific Officer and Director of AmbRx, as Vice President of Research at Amgen, and as Senior Vice President of Discovery Research at Immunex Corporation. Tom is currently a director at Juno Therapeutics and Zafgen, Inc. Tom is Founding Director of Catalysis Advisors and is a venture partner at ARCH Venture Partners. He serves on the Biomedical Science Advisory Board of Vanderbilt University Medical Center, is a member of the Therapeutic Advisory Board of aTyr Pharma, and is a senior advisor to BlackThorn Therapeutics. A nephrologist and former academic investigator, Tom was previously C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt. He earned his medical degree from the University of Texas Southwestern (UTSW), trained in molecular genetics at UTSW, and completed a medical residency at Massachusetts General Hospital.